Gipertrofik kardiomiopatiyaning obstruktiv shaklida yurakning remodellashuv xususiyatlari, Morrou bo’yicha mioektomiyaning samaradorligi
Annotatsiya
Obstruktiv gipertrofik kardiomiopatiya (OGKMP)– genetik omillar tufayli yurakning remodellashuvi bilan kechuvchi kasallikdir. OGKMP chap qorinchaning chiqish yoʻlida dinamik obstruksiya, diastolik disfunksiya, mitral regurgitatsiya, miokard ishemiyasi va yurak ritmi buzilishlari rivojlanishiga sabab boʻlishi mumkin. Klinik jihatdan bemorlarda yurak yetishmovchiligi belgilari bilan namoyon boʻladi. OGKMP, ayniqsa, yoshlarda va sportchilar orasida to‘satdan yurak o‘limining eng keng tarqalgan sababi hisoblanadi. AQSh va Yevropa davlatlarida oʻtkazilgan epidemiologik kuzatuv natijalariga ko‘ra, 35 yoshgacha bo‘lgan sportchilarda to‘satdan yurak o‘limi 30–40% holatlarda OGKMP bilan bog‘liq. Bugungi kunda, kasallikni davolashning zamonaviy noinvaziv usullari mavjudligiga qaramay, xirurgik usul samaradorligi ustun kelmoqda. Maqolada ushbu kasallikda yurakning remodellashuv xusussiyatlari, ushbu yoʻnalishda olib borilgan klinik tadqiqotlar natijalari va davo usullarining samaradorligi haqida adabiyotlarda keltirilgan ma’lumotlar tahlil qilinadi.
Mualliflar haqida
Adabiyotlar ro'yxati
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I (2023) Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 44(44):4622–4633.
Capota R, Militaru S, Ionescu AA, Rosca M, Baicus C, Popescu BA et al (2020) Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes 18:1–8.
Dong T, Alencherry B, Ospina S, Desai MY (2023) Review of mavacamten for obstructive hypertrophic cardiomyopathy and future directions. Drug Des Devel Ther 17:1097–1106
Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-24. https://doi.org/10.1053/euhj.2002.3285.
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649–2660. https://doi.org/10.1016/j.jacc.2020.03.064.
Keen, S., Desai, M. Y. (2025). Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal. Future Cardiology, 21(7), 527–537. https://doi.org/10.1080/14796678.2025.2501466.
Kubo T, Ochi Y, Baba Y, Sugiura K, Takahashi A, Hirota T et al (2020) Elevation of high-sensitivity cardiac troponin T and left ventricular remodelling in hypertrophic cardiomyopathy. ESC Heart Fail 7(6):3593–3600.
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390:1849–1861
Masri A, Cardoso RN, Abraham TP, et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy. J Am Coll Cardiol. 2024;84(19):1806–1817. https://doi.org/10.1016/j.jacc.2024.08.015.
Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg 1961;154:181-89. https://doi.org/10.1097/00000658-196108000-00003.
Ntelios D, Georgiou E, Alexouda S, Malousi A, Efthimiadis G, Tzimagiorgis G (2022) A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy. Heart Fail Rev 27:281
Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759–769.
Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American heart Association/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2024;149(23):e1239–e1311. https://doi.org/10.1161/CIR.0000000000001250.
Rader F, Oręziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. JACC Heart Fail. 2024;12(1):164–177. https://doi.org/10.1016/j.jchf.2023.09.028.
Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, Wang W, Carpino P, Maron BJ, Maron MS, Chen FY. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Car diothorac Surg. 2017 Jul;6(4):353-363. https://doi.org/10.21037/acs.2017.07.07. PMID: 28944176; PMCID: PMC5602194.
Sarwer, K., Lashari, S., Rafaqat, N. et al. Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond. Egypt Heart J 76, 156 (2024). https://doi.org/10.1186/s43044-024-00587-y.
Smedira, N. G., Lytle, B. W., Lever, H. M., Rajeswaran, J., Krishnaswamy, G., Kaple, R. K., Dolney, D. O., Blackstone, E. H. (2008). Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. The Annals of thoracic surgery, 85(1), 127–133. https://doi.org/10.1016/j. athoracsur.2007.07.063.
Watkins H (2021) Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation 143(25):2415–2417
Yun Zhao, Chenhe Li, Dazhong Tang, Yi Luo, Chunlin Xiang, Lu Huang, Xiaoyue Zhou, Jing Fang, Xiang Wei, Liming Xia„Early reverse remodeling of left heart morphology and function evaluated by cardiac magnetic resonance in hypertrophic obstructive cardiomyopathy after transapical beating-heart septal myectomy, Journal of Cardiovascular Magnetic Resonance, Volume 25, Issue 1, 2023, 70, ISSN 1097-6647, https://doi.org/10.1186/s12968-023-00987-0.
Zhu A, Bews H, Cheung D, Nagalingam RS, Mittal I, Goyal V et al (2020) Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study. Can J Physiol Pharmacol 98(7):459–465
Bockeria L.A., Shlyakhto E.V., Gabrusenko S.A., Gudkova A.Ya., Koziolova N.A., Aleksandrova S.A., Alekhin M.N., Afanasyev A.V., Bogatyreva M.M., Bogachev-Prokofiev A.V., Bogdanov D.V., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Evtushenko A.V., Zaklyazminskaya E.V., Zenchenko D.I., Irtyuga O.B., Kaplunova V.Yu., Kashtanov M.G., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Rud S.D., Rybka M.M., Saidova M.A., Streltsova A.A., Stukalova O.V., Chmelevsky M.P., Shaposhnik I.I., Shloydo E.A. Hypertrophic Cardiomyopathy. Clinical Guidelines 2025. Russian Journal of Cardiology. 2025;30(5):6387. https://doi.org/10.15829/1560-4071-2025-6387.EDN:BUUCJT.
Raskin V.V., Frolova Yu.V., Malikova M.S., Dzemeshkevich A.S., Dombrovskaya A.V., Shapieva Albina Nurullayevna, Fedulova S.V., Dzemeshkevich S.L. (2014). Surgical Treatment Strategy for Patients with the Generalized Form of Obstructive Hypertrophic Cardiomyopathy. Clinical and Experimental Surgery, 1(3), 100–103.
Seidalin A.O., Albazarov A.B., Tozhiboev R.E., Nurakaeva S.S., Sygai A.I., Dikolaev V.D. (2015). Surgical Treatment of Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine of Kazakhstan, 1(35), 21–25.
Copyright (c) 2025 Н. Расулова, Т.А. Абдуллаев, А.А. Хакимов (Автор)
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution» (««Atribut») 4.0 Butun dunyo bo'ylab.